Get started
Author

Michele Kosh

Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · Caroline Robert, Jacob Schachter, et al. · New England Journal of Medicine · 5,879
PDF
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study
2020 · Ajai Chari, Paula Rodriguez‐Otero, et al. · British Journal of Haematology · 64
PDF
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
2023 · Meletios A Dimopoulos, Evangelos Terpos, et al. · The Lancet Haematology · 48
A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule
2008 · M. Hidalgo, M. Tirado Gomez, et al. · Journal of Clinical Oncology · 47
Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors
2006 · I. E. Krop, M. Kosh, et al. · Journal of Clinical Oncology · 39
Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
2022 · Meletios A. Dimopoulos, Evangelos Terpos, et al. · Blood · 15
Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)
2019 · Ajai Chari, Hartmut Goldschmidt, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
2023 · Philippe Moreau, Ajai Chari, et al. · Blood Cancer Journal · 8
PDF
Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update
2019 · Ajai Chari, Jesús San-Miguel, et al. · Blood · 6
Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody
2024 · Ajay K. Nooka, Hira Mian, et al. · Blood · 4
Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts
2020 · Philippe Moreau, Ajai Chari, et al. · Blood · 3
Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma
2015 · Antoni Ribas, Jacob Schachter, et al. · Cancer Research · 3
Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study
2021 · Pieter Sonneveld, Evangelos Terpos, et al. · Blood · 2
Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)
2019 · Ajai Chari, Hartmut Goldschmidt, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Works count: 14
Citation count: 6,130
H-index: 8
I10-index: 7
Year
Topic
Type